Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q5SW96
UPID:
ARH_HUMAN
Alternative names:
Autosomal recessive hypercholesterolemia protein
Alternative UPACC:
Q5SW96; A2BHI5; Q6TQS9; Q8N2Y0; Q9UFI9
Background:
Low density lipoprotein receptor adapter protein 1, also known as the autosomal recessive hypercholesterolemia protein, plays a crucial role in lipid metabolism. It acts as an adapter protein necessary for the efficient endocytosis of the LDL receptor in specific cells, facilitating the internalization of LDL and its receptor from coated pits. This protein's interaction with phosphoinositides is vital for clathrin bud assembly at the cell surface.
Therapeutic significance:
Given its pivotal role in lipid metabolism and the endocytosis of LDL receptors, Low density lipoprotein receptor adapter protein 1 is directly linked to familial hypercholesterolemia, type 4. This association highlights its potential as a target for therapeutic strategies aimed at treating or managing hypercholesterolemia and its complications, such as atherosclerosis and coronary heart disease.